Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

Wyeth logo

Wyeth

Status and phase

Terminated
Phase 3
Phase 2

Conditions

Fibromyalgia

Treatments

Drug: DVS-233

Study type

Interventional

Funder types

Industry

Identifiers

NCT00301431
3151A4-327

Details and patient eligibility

About

The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Fibromyalgia according to 1990 American College of Rheumatology (ACR) criteria

Exclusion criteria

  • Other painful conditions that may make results difficult to interpret.
  • Treatment with other drugs for fibromyalgia with 14 days of study start or during the study.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems